These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 33486718)

  • 1. Pharmacokinetics of Roxadustat: A Population Analysis of 2855 Dialysis- and Non-Dialysis-Dependent Patients with Chronic Kidney Disease.
    Rekić D; Kerbusch-Herben V; Någård M; Chou J; Huang J; Bradley C; Åstrand M; Tannenbaum S; Hamrén B
    Clin Pharmacokinet; 2021 Jun; 60(6):759-773. PubMed ID: 33486718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of roxadustat in Japanese dialysis-dependent chronic kidney disease patients with anaemia.
    Takada A; Shibata T; Shiga T; Groenendaal-van de Meent D; Komatsu K
    Br J Clin Pharmacol; 2022 Feb; 88(2):787-797. PubMed ID: 34350625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
    Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
    Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Food and Spherical Carbon Adsorbent Effects on the Pharmacokinetics of Roxadustat in Healthy Nonelderly Adult Male Japanese Subjects.
    Shibata T; Nomura Y; Takada A; Ueno M; Katashima M; Yazawa R; Furihata K
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):304-313. PubMed ID: 29966038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
    Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
    Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R; Tumlin J; Zabaneh R; Chou J; Hemmerich S; Neff TB; Yu KP
    J Clin Pharmacol; 2020 Nov; 60(11):1432-1440. PubMed ID: 32603526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
    Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
    Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Groenendaal-van de Meent D; Kerbusch V; Kaspera R; Barroso-Fernandez B; Galletti P; Klein GK; den Adel M
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):141-153. PubMed ID: 33165773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
    Shibata T; Nomura Y; Takada A; Aoki S; Katashima M; Murakami H
    J Clin Pharm Ther; 2018 Oct; 43(5):633-639. PubMed ID: 29981285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.
    Tian L; Wang M; Liu M; Pang Y; Zhao J; Zheng B; Wang Y; Zhao W
    Ren Fail; 2024 Dec; 46(1):2313864. PubMed ID: 38345037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
    Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy Individuals.
    Groenendaal-van de Meent D; Kerbusch V; Barroso-Fernandez B; den Adel M; van Dijk J; Golor G; Schaddelee M
    Clin Ther; 2021 Jun; 43(6):1079-1091. PubMed ID: 33962762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
    Barratt J; Andric B; Tataradze A; Schömig M; Reusch M; Valluri U; Mariat C
    Nephrol Dial Transplant; 2021 Aug; 36(9):1616-1628. PubMed ID: 34077510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
    J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.
    Mata Lorenzo M; Ali M; Mealing S; Moss J
    J Med Econ; 2023; 26(1):1250-1260. PubMed ID: 37752891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Expert Opin Pharmacother; 2022 Jan; 23(1):19-28. PubMed ID: 34686069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.